Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Ultragenyx Pharmaceutical Inc. (RARE)

Pharmaceutical Preparations

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

60 LEVERONI COURT
NOVATO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/31/2014

Market Cap

4,886,598,904

Shares Outstanding

82,110,000

Weighted SO

82,114,350

Total Employees

N/A

Upcoming Earnings

N/A

Beta

0.5600

Last Div

0.0000

Range

31.52-54.56

Chg

1.2900

Avg Vol

888577

Mkt Cap

4886598904

Exch

NASDAQ

Country

US

Phone

415 483 8800

DCF Diff

4.2948

DCF

39.4252

Div Yield

0.0000

P/S

10.1529

EV Multiple

-10.5023

P/FV

10.6159

Div Yield %

0.0000

P/E

-7.8454

PEG

-0.2057

Payout

0.0000

Current Ratio

3.5352

Quick Ratio

3.3881

Cash Ratio

1.7843

DSO

82.1165

DIO

184.1424

Op Cycle

266.2590

DPO

274.3854

CCC

-8.1264

Gross Margin

0.8347

Op Margin

-1.1404

Pretax Margin

-1.2193

Net Margin

-1.2157

Eff Tax Rate

0.0030

ROA

-0.3615

ROE

-2.6602

ROCE

-0.4079

NI/EBT

0.9970

EBT/EBIT

1.0692

EBIT/Rev

-1.1404

Debt Ratio

0.5566

D/E

2.0832

LT Debt/Cap

0.6607

Total Debt/Cap

0.6757

Int Coverage

-15.7355

CF/Debt

-0.5212

Equity Multi

3.7428

Rec Turnover

4.4449

Pay Turnover

1.3302

Inv Turnover

1.9822

FA Turnover

1.7269

Asset Turnover

0.2974

OCF/Share

-5.4223

FCF/Share

-5.6882

Cash/Share

8.8934

OCF/Sales

-0.9754

FCF/OCF

1.0490

CF Coverage

-0.5212

ST Coverage

-8.0062

CapEx Coverage

-20.3983

Div&CapEx Cov

-20.3983

P/BV

10.6159

P/B

10.6159

P/S

10.1529

P/E

-7.8454

P/FCF

-9.9224

P/OCF

-9.7781

P/CF

-9.7781

PEG

-0.2057

P/S

10.1529

EV Multiple

-10.5023

P/FV

10.6159

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 30, 21:00 Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update GlobeNewswire Inc. Jan 17, 21:30 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 09, 15:30 Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit GlobeNewswire Inc. Jun 14, 00:49 Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire Inc. May 28, 06:00 Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH) Benzinga Jan 19, 10:00 4 Analysts Have This To Say About Ultragenyx Pharmaceutical GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones GlobeNewswire Inc. Jan 07, 11:00 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

Revenue Product Segmentation